1. Bustillos E, Zepeda J, Hernández MA, Briones CH. Anticoncepción con hormonales combinados en ciclos extendidos artificialmente. Ginecol Obstet Mex. 2010; 78 (1): 37 – 45.

2. World Health Organization. Unsafe abortion: global and regional estimates of incidence of unsafe abortion and associated mortality in 2008. 6ta edición. Department of Reproductive Health and Research, World Health Organization: Ginebra. 2011. 56 pp.

3. Beltrán DA. Anticoncepción Hormonal Combinada: Aspectos metabólicos y clínicos según las diferentes vías de administración y gestágeno utilizado. Tesis doctoral. Universidad de Salamanca. Facultad de Medicina. 2009, [Tesis en línea]. Disponible en:http://gredos.usal.es/jspui/bitstream/10366/76214/1/DOGP_Beltran_D_Impactoclinicoymetabolicodelosanticoceptivos.pdf.Fecha de recuperación: 05 de Mayo de 2012.

4. Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM. Anticonceptivos combinados: efectos sobre el peso. La Biblioteca Cochrane Plus, Issue 3, 2008. Oxford: Update Software. [Documento en línea]. Disponible en:http://www.thecochranelibrary.com. Fecha de recuperación: 28 de Abril de 2012.

5. Lloyd T, Lin HM, Matthews AE, Bentley CM, Legro RS. Oral Contraceptive Use by Teenage Women Does Not Affect Body Composition. Obstet Gynecol. 2002; 100 (2): 235 – 239.

6. Gaudet LM, Kives S, Hahn PM, Reid RL. What women believe about oral contraceptives and the efffect of counseling. Contraception. 2004; 69 (1):31 - 36.

7. Le MG, Laveissiere MN, Pelissier C. Factors associated with weight gain in women using oral contraceptives: results of a French 2001 opinion poll survey conducted on 1665 women. Gynecol Obstet Fertil. 2003; 31 (3):230 -239.

8. De la Cuesta R, Franco C, Iglesias E. Actualización en anticoncepción hormonal. Inf Ter Sist Nac Salud. 2011; 35 (3): 75 – 87.

9. Bhattacharya P, Kapoor N, Kyal A, Mukhopadhyay P. A Comparative Study of Drospirenone and Desogestrel: An Overview of Benefi ts and Side Effects. NJOG.2011; 6 (1): 17 – 21.

10. Batukan C, Muderris II, Ozcelik B, Orturz A. Comparicion of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutims. Gynecol. Endocrinol. 2007; 23 (1): 38 – 44.

11. Bachmann G, Kopacz, S. Drospirenone/ethinyl estradiol 3 mg/20 μg (24/4 day regimen): hormonal contraceptive choices – use of a fourth-generation progestin.Patient Prefer Adherence. 2009; 3: 259 – 264.

12. Pérez FR. Clinical experiences with drospirenone: From reproductive to postmenopausal years. Maturitas. 2008; 60 (2): 78 – 91.

13. Villanueva LA, Pichardo M. Adelantos en anticoncepción hormonal. Ginecol Obstet Mex. 2007; 75 (1): 35 – 42.

14. Klipping C,Duijkers I, Trummer D, Marr J. Suppression of ovarían activity with a drosperinone-containing oral contraceptive in a 24/4 regimen. Contraception. 2008; 78: 16 – 25.

15. Cronin M, Schellschmidt I, Dinger J. Rate of Pregnancy After Using Drospirenone and Other Progestin-Containing Oral Contraceptives. Obstet Gynecol. 2009; 114 (3): 616 – 622.

16. Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of Thromboembolism in Women Taking Ethinylestradiol/Drospirenone and Other Oral Contraceptives. Obstet Gynecol. 2009; 110 (3): 587 – 593.

17. Sitruk-Ware R, Nath A. The use of newer progestins for contraception. Contraception. 2010; 82 (5): 410 - 417.

18. Le YC, Rahman M, Berenson AB. Early weight gain predicting later weight gain among depot medroxyprogesterone acetate users. Obstet Gynecol. 2009; 114 (2): 279 – 284.

19. Bonny AE, Secic M, Cromer B. Early Weight Gain Related to Later Weight Gain in Adolescents on Depot Medroxyprogesterone Acetate. Obstet Gynecol. 2011; 117 (4): 793 – 797.

20. Yela DA, Urbano IM, Bahamondes LG, Del Castillo S, Bahamondes MV, Fernandes A. Variação de peso em usuárias de sistema intra-uterino liberador de levonorgestrel, diu t-cobre e acetato de medroxiprogesterona no Brasil. Rev Assoc Med Bras. 2006; 52 (1): 32 – 36.

21. World Health Organization. Obesity: Preventing and managing the global epidemic. World Health Organ Tech Rep Ser. No. 894. OMS: Ginebra, Suiza. 2000. 265 pp.

22. Lean M, Han T, Morrison N. Waist circunference indicates the need for weight management. BMJ. 2005; 311 (2): 158-161.

23. Despréss JP, Lemieux I, Prud´homme D. Treatment of Obesity: need to focus on high risk abdominally obese patients. BMJ. 2001; 322: 716 – 720.

24. Endrikat J. A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 microg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight.Eur J Contracept Reprod Health Care. 2007; 12 (3): 220 – 228.

25. Lindh I, Andersson A, Milsom I. The long-term influence of combined oral contraceptives on body weight. Hum. Reprod. 2011; 26 (7): 1917 - 1924.

26. Borges LE, Andrade RP, Aldrighi JM, Guazelli C, Yazlle ME, Isaia CF, et al. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception. Contraception. 2006; 74 (6): 446 - 450.

27. Milsom I, Lete I, Bjertnaes A, Rokstad K, Lindh I, Gruber CJ, et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 mg ethinyl estradiol and 3 mg drospírenona. Hum Reprod. 2006; 21 (9): 2304 – 2311

28. Tfayli H, Ulnach JW, Lee SJ, Sutton-Tyrrell K, Arslanian S. Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors. J Clin Endocrinol Metab. 2011; 96 (5): 1311 - 1319.

29. Mohamed AM, El-Sherbiny WS, Mostafa WA. Combined contraceptive ring versus combined oral contraceptive (30-μg ethinylestradiol and 3-mg drospirenone). Int J Gynaecol Obstet. 2011; 114 (2): 145 - 148.

30. Guang-Sheng F, Mei-Lu B, Li-Nan C, Xiao-Ming C, Zi-Rong H, Zi-Yan H, et al.Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial. Clin Drug Investig. 2010; 30 (6): 387 - 396.

31. Fan GS, Bian ML, Cheng LN, Cao XM, Huang ZR, Han ZY, et al. Efficacy and safety of drospirenone-ethinylestradiol on contraception in healthy Chinese women: a multicenter randomized controlled trial. Zhonghua Fu Chan Ke Za Zhi. 2009; 44 (1): 38 - 44.

32. Yildizhan R, Yildizhan B, Adali E, Yoruk P, Birol F, Suer N. Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure. Arch Gynecol Obstet. 2009; 280 (2): 255 – 261.

33. Sangthawan M, Taneepanichskul S. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms. Contraception. 2005; 71 (1): 1 - 7.

34. Suthipongse W, Taneepanichskul S. An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 microg ethinylestradiol and 150 microg levonogestrel/30 microg ethinylestradiol in Thai women.Contraception. 2004; 69 (1): 23 – 26.

35. Centeno IM, Gonzalez NJ, Cáceres MG. Efecto de un anticonceptivo oral con drospirenona/etinilestradiol (3 mg - 30 mg) sobre el hiperandrogenismo clínico y bioquímico en pacientes con síndrome de ovario poliquístico. Rev. Fac. Med. (Caracas). 2011; 34 (1): 60 - 63.

36. Kriplani A, Periyasamy AJ, Agarwal N, Kulshrestha V, Kumar A, Ammini AC.Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary síndrome. Contraception. 2010; 82 (2): 139 -146.

37. Ilie IR, Marian I, Mocan T, Ilie R, Mocan L, Duncea I, et al. Ethinylestradiol30μg-drospirenone and metformin: could this combination improve endothelial dysfunction in polycystic ovary syndrome?. BMC Endocr Disord. 2012; 12 (9) [Periódico en línea]. Disponible en: http://www.biomedcentral.com/content/pdf/1472-6823-12-9.pdf.Fecha de recuperación: 14 de Noviembre de 2014.

38. Aydin K, Cinar N, Aksoy DY, Bozdag G, Yildiz BO. Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination. Contraception. 2013; 87(3): 358 - 362.

39. Kaya MG, Calapkorur B, Karaca Z, Yildirim S, Celik A, Akpek M, et al. The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2012; 77 (6): 885 - 892.

40. Cinar N, Harmanci A, Bayraktar M, Yildiz BO. Ethinyl estradiol–drospirenone vs ethinyl estradiol–drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2013; 78 (3): 379 - 384.

41. Foidart JM, Faustmann T. Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen. Gynecol Endocrinol. 2007; 23 (12): 692 - 699.

42. Fruzzetti F. Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention. Contraception. 2007; 76 (3): 190 – 194.

De Morais S, Taquette SR. Factores asociados al abandono de la anticoncepción hormonal oral: un estudio con los adolescentes de la ciudad de Rio De Janeiro. Rev Chil Obstet Ginecol. 2007; 72 (1): 26-32.